



"Understanding the Role of Hypertension in Atherosclerosis and Myocardial Infarction: Implications for Prevention and Management"

Ms. Niharika Tiwari^{1*}, Prof. R. Sreeraja Kumar², Z. Naveen Kumar³, Ms. Seema ⁴, Ms. Neha Srivastava⁵, Dr. Pallavi Prakash⁶

¹*FMERC/FMERU, Assistant Professor, Department of Medical Surgical Nursing (Cardiovascular Thoracic Nursing), Sharda School of Nursing Science & Research, Sharda University, Greater Noida (UP), India.

²Associate Dean, Sharda School of Nursing Science & Research, Sharda University, Greater Noida (UP), India.

³Assistant Professor, Department of Physiology, Santhiram Medical College & General Hospital, Nandyal, Andhra Pradesh, India

⁴Senior Tutor, Department of Child Health Nursing, Sharda School of Nursing Science & Research, Sharda University, Greater Noida (UP), India.

⁵Nursing Lecturer, Department of Child Health Nursing, Prakash Institute of Physiotherapy Rehabilitation & Allied Medical Sciences, Greater Noida (UP), India.

⁶Assistant Professor, School of Allied Health Sciences, Noida International University, Greater Noida (UP), India.

***Corresponding Author:** Ms. Niharika Tiwari

*FMERC/FMERU Assistant Professor, Department of Medical Surgical Nursing Sharda School of Nursing Science & Research, Sharda University Greater Noida, India.

(Received: 02 September 2023

Revised: 14 October

Accepted: 07 November)

KEYWORDS:

Atherosclerosis,
Cardiovascular Disease, Early
Intervention. Endothelial
Dysfunction, Hypertension,
Myocardial Infarction,
Lifestyle Modification,
Patient Education, Prevention,
Public Health Campaigns,
Risk Factors

ABSTRACT

Introduction: Myocardial Infarction (MI), or heart attack, is a global health concern and a leading cause of cardiovascular mortality. MI occurs due to the sudden interruption of blood supply to a portion of the heart muscle, primarily caused by the occlusion of coronary arteries. This critical condition is influenced by various risk factors, including hypertension, hyperlipidemia, smoking, and diabetes. Among these factors, hypertension plays a central role in the development and progression of atherosclerosis, a key precursor to MI. This manuscript provides a comprehensive understanding of how hypertension interacts with atherosclerosis and MI and explores the implications for prevention and management.

Methods: The manuscript begins with an introduction highlighting the significance of MI, its high mortality rate, sudden onset, complications, chronic consequences, risk factors, global prevalence, and the importance of awareness and prevention. It also underscores the need for a detailed examination of the pathophysiological journey from atherosclerosis to MI to enhance our knowledge and improve strategies for diagnosis, treatment, and prevention.

Results: The manuscript then delves into a comprehensive analysis of risk factors, with a focus on hypertension. It explains how hypertension leads to endothelial damage, dysfunction, inflammation, and oxidative stress, promoting the initiation and progression of atherosclerosis. The synergistic effects of risk factors and their interrelationships are highlighted, emphasizing the importance of addressing multiple risk factors in atherosclerosis prevention.

Discussion: Preventive measures and management strategies, including public health campaigns, smoking cessation programs, dietary interventions, physical activity promotion, and regular health checkups, are discussed in the context of reducing cardiovascular risk. The manuscript emphasizes the role of patient education and awareness in recognizing risk factors and symptoms, seeking prompt medical attention, and adhering to heart-healthy behaviors.

Conclusion: In conclusion, this manuscript underscores the complex relationship between hypertension, atherosclerosis, and MI and highlights the significance of



comprehensive preventive strategies. Educating individuals about the risk factors and symptoms of heart disease is essential for reducing the overall burden of cardiovascular diseases and promoting cardiovascular health. This multi-pronged approach, involving healthcare providers, public health agencies, policymakers, and informed individuals, holds the key to improving cardiovascular outcomes and reducing the incidence of MI.

Introduction:

Myocardial Infarction (MI), commonly known as a heart attack, is a critical medical condition characterized by the sudden and severe interruption of blood supply to a portion of the heart muscle (myocardium). This interruption occurs due to the occlusion or blockage of one or more coronary arteries, typically by a blood clot, which leads to damage or death of the affected heart muscle tissue.

MI is considered a leading cause of cardiovascular mortality for several reasons:

Mortality Rate: Myocardial infarction has a high mortality rate and is a major contributor to overall cardiovascular deaths worldwide. This is primarily because it can result in the rapid deterioration of heart function and, if not treated promptly, can lead to fatal complications.¹

Sudden Onset: Heart attacks can occur suddenly and without warning, often leading to life-threatening situations. This sudden onset means that individuals experiencing an MI may require immediate medical attention to increase their chances of survival.²

Complications: Myocardial infarction can give rise to various complications, including arrhythmia (irregular heart rhythms), heart failure, cardiogenic shock, and cardiac arrest. These complications can be fatal if not managed promptly and effectively.³

Chronic Consequences: Survivors of MI are at an increased risk of long-term cardiovascular complications, including recurrent heart attacks, heart failure, and reduced cardiac function. These chronic consequences can contribute to increased mortality rates over time.⁴

Risk Factors: Many risk factors, such as hypertension, hyperlipidemia, smoking, diabetes, and a family history of cardiovascular disease, increase the likelihood of developing MI. These risk factors are prevalent in many populations, contributing to MI's status as a leading cause of cardiovascular mortality.

Global Prevalence: MI is a global health concern, affecting individuals of all ages and backgrounds. It is not limited to specific regions or populations, making it

a significant contributor to cardiovascular mortality on a global scale.

Awareness and Prevention: While there have been significant advancements in diagnosing and treating MI, prevention and early intervention remain crucial. Raising awareness about the risk factors, symptoms, and lifestyle modifications that can reduce the risk of MI is essential to reducing its mortality impact.⁵

The aim of the manuscript is to provide a comprehensive understanding of the progression of Myocardial Infarction (MI) from its initial stages involving atherosclerosis to the critical event of thrombosis within the coronary arteries. This manuscript seeks to explore the intricate mechanisms that underlie this progression and to elucidate the clinical implications associated with each step of this pathophysiological journey. Through a detailed examination of the processes involved, this manuscript aims to enhance our knowledge of MI, ultimately contributing to improved diagnosis, treatment, and prevention strategies for this life-threatening cardiovascular condition.⁶

Atherosclerosis is a multifactorial and complex cardiovascular condition, and several risk factors contribute to its development and progression. Among the most significant risk factors are hypertension, hyperlipidemia, smoking, and diabetes. Let's discuss how each of these risk factors contributes to atherosclerosis:

Hypertension (High Blood Pressure):

1. Endothelial Damage: Hypertension exerts chronic pressure and force on the arterial walls. Over time, this pressure can lead to damage or injury to the endothelium, the inner lining of arteries.

2. Endothelial Dysfunction: Damaged endothelial cells lose their normal protective function and become dysfunctional. This dysfunction impairs the endothelium's ability to regulate blood vessel tone and maintain a healthy environment within the arteries.⁷

3. Inflammation and Oxidative Stress: Hypertension can promote inflammation and oxidative stress within the arterial wall. These processes contribute to the initiation and progression of atherosclerosis by attracting immune cells to the damaged sites and facilitating the accumulation of lipids within the arterial wall.



Hyperlipidemia (High Blood Lipid Levels):

1. **LDL Cholesterol:** Elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad cholesterol," are a key contributor to atherosclerosis. LDL cholesterol can infiltrate the arterial wall and become trapped in the subendothelial space, initiating the formation of atherosclerotic plaques.
2. **Oxidized LDL:** When LDL cholesterol is exposed to oxidative stress within the arterial wall, it becomes modified or oxidized. Oxidized LDL is particularly atherogenic (promotes atherosclerosis) and can trigger inflammation and immune responses.⁸

Smoking:

1. **Endothelial Damage:** Smoking damages the endothelium directly through the toxic components of tobacco smoke. This damage compromises the endothelium's function and integrity.
2. **Inflammation:** Smoking promotes inflammation within the arterial wall, attracting immune cells and contributing to the formation of fatty streaks and atherosclerotic plaques.
3. **Oxidative Stress:** Smoking generates oxidative stress, which not only oxidizes LDL cholesterol but also damages the endothelium and promotes a pro-atherogenic environment.

Diabetes (Type 2 Diabetes Mellitus):

1. **Insulin Resistance:** In type 2 diabetes, the body becomes resistant to insulin, leading to elevated blood glucose levels. Insulin resistance is associated with a pro-inflammatory state and impaired endothelial function.
2. **Hyperglycemia:** High blood glucose levels can directly damage endothelial cells and promote inflammation. This contributes to endothelial dysfunction and atherosclerosis.
3. **Dyslipidemia:** People with type 2 diabetes often have abnormal lipid profiles, including elevated triglycerides and decreased high-density lipoprotein (HDL) cholesterol, which can further promote atherosclerosis.⁴ It's important to note that these risk factors are often interrelated. For example, hypertension can exacerbate the effects of hyperlipidemia, and smoking can worsen the impact of both hypertension and hyperlipidemia on atherosclerosis. Additionally, genetics and lifestyle factors, such as diet and physical activity, play roles in the development of atherosclerosis.⁹

Preventive measures and management strategies for atherosclerosis often involve addressing these risk factors. Lifestyle modifications, including adopting a heart-healthy diet, regular exercise, smoking cessation, and managing blood pressure, cholesterol, and glucose levels, are essential components of atherosclerosis prevention and management.

Methods:

1. Literature Review: A comprehensive review of existing literature was conducted to gather data and insights related to the interplay between hypertension and atherosclerosis. Databases including PubMed, Google Scholar, and relevant medical journals were searched for peer-reviewed articles, reviews, and clinical studies. The key search terms included "hypertension," "atherosclerosis," "endothelial damage," "inflammation," "cardiovascular complications," and "prevention."

2. Data Compilation: Data pertaining to the mechanisms involved in the development of atherosclerosis, particularly in the context of hypertension, were compiled. This involved collecting information on the role of hypertension in endothelial damage, inflammation, and oxidative stress. The relationships between hypertension, lipid profiles, and atherosclerosis were explored, including the impact of hypertension on LDL cholesterol levels.¹⁰

3. Risk Factor Analysis: A detailed analysis of risk factors contributing to atherosclerosis was conducted. Specific attention was given to hypertension, hyperlipidemia, smoking, and diabetes, and how each of these factors individually and interactively contributes to atherogenesis. The role of hypertension in facilitating lipid entry into the arterial wall was emphasized, as well as its interactions with other risk factors.

4. Synthesis of Findings: The data gathered from the literature review and risk factor analysis were synthesized to provide a comprehensive understanding of how hypertension interacts with atherosclerosis. Mechanisms involving endothelial damage, inflammation, oxidative stress, and lipid infiltration were integrated to elucidate the complex relationship between hypertension and atherosclerosis.¹¹

5. Discussion of Prevention and Management: The manuscript discussed preventive measures and management strategies for atherosclerosis in the context of hypertension. The importance of addressing risk factors through lifestyle modifications, such as smoking cessation, dietary interventions, and physical activity promotion, was highlighted. The role of public health campaigns and healthcare interventions in raising awareness and providing early intervention was explored.¹²

6. Patient Education and Awareness: The role of patient education in recognizing risk factors and symptoms of heart disease was emphasized. The importance of early intervention and seeking prompt medical attention when experiencing symptoms of myocardial infarction was discussed. The impact of educated patients in adhering to treatment regimens and adopting heart-healthy behaviors was underlined.¹³



In conclusion, the methods employed in this manuscript involved a comprehensive literature review, data compilation, risk factor analysis, synthesis of findings, and a discussion of prevention and management strategies for atherosclerosis, with a focus on hypertension. Patient education and awareness were central to the approach, aiming to promote heart-healthy behaviors and improve cardiovascular outcomes.

Results:

The Interplay Between Hypertension and Atherosclerosis: The comprehensive analysis of the interplay between hypertension and atherosclerosis revealed intricate mechanisms that connect these two cardiovascular conditions. Hypertension was found to play a significant role in the development and progression of atherosclerosis by causing chronic damage to the endothelium, promoting endothelial dysfunction, and contributing to inflammation and oxidative stress within the arterial wall. This damage facilitated the entry of lipids, particularly LDL cholesterol, into the arterial wall, initiating the formation of atherosclerotic plaques. **Synergistic Effects of Risk Factors:** The results highlighted that hypertension, hyperlipidemia, smoking, and diabetes are interrelated risk factors, and their effects can synergistically exacerbate the progression of atherosclerosis. For instance, hypertension can worsen the impact of hyperlipidemia by further damaging the endothelium, while smoking enhances inflammation and oxidative stress, amplifying the atherogenic environment. **Preventive Strategies:** The discussion of preventive measures revealed the significant impact of public health campaigns, smoking cessation programs, and dietary interventions in raising awareness and promoting heart-healthy behaviors. The success of these campaigns was evident in increasing public awareness of risk factors and motivating individuals to assess their own risk for cardiovascular diseases.¹⁴

Physical Activity Promotion and Health Checkups: The promotion of physical activity and regular health checkups was found to be essential in the early identification and management of cardiovascular risk factors. Creating environments that encourage physical activity at the community level, along with regular health assessments, contributes to primary prevention and early intervention. **Patient Education and Awareness:** The results emphasized that patient education and awareness are powerful tools in reducing the incidence of Myocardial Infarction. Educated patients are more likely to recognize risk factors and symptoms, leading to prompt medical attention. Informed individuals are also more likely to adhere to treatment regimens and adopt heart-healthy behaviors, contributing to long-term risk reduction.¹⁵

In conclusion, the results of this manuscript underscore the intricate relationship between hypertension and atherosclerosis and its role in the development of Myocardial Infarction. Furthermore, the manuscript highlights the importance of addressing risk factors through comprehensive preventive strategies, including public health campaigns, lifestyle modifications, and early intervention. Educating individuals about the risk factors and symptoms of heart disease is a critical component of reducing the overall burden of cardiovascular diseases and promoting cardiovascular health. These findings contribute to our understanding of the complexities of heart disease and provide insights into strategies for improving diagnosis, treatment, and prevention in the context of atherosclerosis and hypertension.^{16,17}

Discussion:

Preventive strategies for reducing the risk of cardiovascular diseases, particularly Myocardial Infarction (MI) or heart attack, are multifaceted and encompass a combination of public health campaigns, lifestyle modifications, and healthcare interventions. This discussion delves into the significance of these preventive measures, emphasizing the vital role they play in reducing the burden of heart disease and promoting cardiovascular health.¹⁸

The Impact of Public Health Campaigns:

Public health campaigns are pivotal in raising awareness about heart disease and motivating individuals to adopt heart-healthy lifestyles. These campaigns inform the public about the risk factors associated with heart disease and empower them to recognize signs and symptoms of heart attacks, highlighting the importance of seeking prompt medical attention. The success of public health campaigns is evident in their ability to educate the population about risk factor identification, leading to an increased consciousness of hypertension, hyperlipidemia, smoking, diabetes, and obesity. By encouraging individuals to assess their own risk and manage it, these campaigns contribute to primary prevention efforts.¹⁹

Smoking Cessation Programs and Dietary Interventions:

The impact of smoking cessation programs and dietary modifications on cardiovascular health cannot be overstated. Smoking cessation programs offer effective strategies, including counseling and nicotine replacement therapy, which are instrumental in reducing cardiovascular risk. Public policies such as taxation, smoke-free environments, and graphic warning labels on cigarette packages complement these programs by discouraging smoking.



Dietary interventions, encompassing heart-healthy eating and reduced sodium and sugar consumption, have the potential to significantly reduce the risk of heart disease. Encouraging the consumption of fruits, vegetables, whole grains, and low-saturated fat foods, along with nutrition labeling, equips individuals to make informed dietary choices. By promoting these interventions, public health campaigns contribute to healthier dietary habits in the population.²⁰

Physical Activity Promotion and Regular Health Checkups:

Physical activity is another cornerstone of cardiovascular health promotion. Public health campaigns that emphasize regular exercise not only encourage individuals to meet recommended exercise guidelines but also promote community initiatives that create accessible environments for physical activity. Building walkable neighborhoods, recreational spaces, and active transportation options fosters physical activity at the community level.²¹

Regular health checkups, encouraged by preventive healthcare campaigns, play a vital role in identifying and managing cardiovascular risk factors. These checkups, which include assessing blood pressure, cholesterol levels, and blood sugar, are instrumental in the early identification and management of risk factors. Combining these efforts with pharmacotherapy when needed ensures that individuals receive appropriate treatment to control conditions like hypertension, hyperlipidemia, or diabetes.

Patient Education and Early Intervention:

Patient education and early intervention are central to reducing the incidence of MI or heart attack. Educated patients are more likely to recognize their own risk factors and make informed decisions regarding lifestyle choices. By understanding the signs and symptoms of a heart attack, individuals are empowered to seek prompt medical attention. Furthermore, educated patients are more likely to adhere to medication regimens and adopt healthy behaviors that contribute to long-term risk reduction and secondary prevention.²²

The population-wide impact of patient education cannot be understated. An informed population is more likely to embrace heart-healthy behaviors, leading to fewer heart attacks and related complications. Ultimately, preventive strategies for reducing the risk of cardiovascular diseases are most effective when implemented comprehensively and involve collaboration among healthcare providers, public health agencies, policymakers, and individuals. This multi-pronged approach holds the key to reducing the overall burden of heart disease and fostering cardiovascular health at the population level.^{23,24}

Conclusion:

In conclusion, patient education and early intervention are powerful tools for reducing the incidence of Myocardial Infarction. By providing individuals with the knowledge and awareness they need to recognize risk factors and act promptly when symptoms occur, we can save lives, preserve heart function, and improve the overall cardiovascular health of our communities. Education is an investment in both individual well-being and public health.

Competing interests

All other authors declare no competing interests.

Funding and Acknowledgment

No funding sources were used in this research, and the authors would like to extend their appreciation to [any individuals or organizations you want to acknowledge] for their support and contributions to this study.

References

1. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. heart disease and stroke statistics-2021 update: a report from the american heart association. *Circulation*. (2021) 23:e254–743. 10.1161/CIR.0000000000000950.
2. Bhatnagar A. Environmental determinants of cardiovascular disease. *Circ Res*. (2017) 121:162–80. 10.1161/CIRCRESAHA.117.306458.
3. Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. *Cochrane Database Syst Rev*. (2018) 7:CD010315.
4. Jo W, Lee S, Joo YS, Nam KH, Yun HR, Chang TI, et al. Association of smoking with incident CKD risk in the general population: A community-based cohort study. *PLoS One*. (2020) 15:e0238111.
5. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta. *Clin Dev Immunol*. (2012) 2012:832464.
6. Blaha MJ, DeFilippis AP. Multi-Ethnic Study of Atherosclerosis (MESA): JACC Focus Seminar 5/8. *J Am College Cardiol*. (2021) 77:3195–216. 10.1016/j.jacc.2021.05.00.
7. Liu K, Colangelo LA, Daviglius ML, Goff DC, Pletcher M, Schreiner PJ, et al. Can antihypertensive treatment restore the risk of cardiovascular disease to ideal levels?: the



- coronary artery risk development in young adults (CARDIA) study and the multi-ethnic study of atherosclerosis (MESA). *J Am Heart Assoc.* (2015) 4:e002275.
8. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the european association for cardiovascular prevention & rehabilitation (EACPR). *Eur Heart J.* (2016) 37:2315–81. doi:10.1093/eurheartj/ehw106
 9. Chistiakov DA, Revin VV, Sobenin IA, Orekhov AN, Bobryshev YV. Vascular endothelium: functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function. *Mini Rev Med Chem.* (2015) 15:338–50. doi:10.2174/1389557515666150226114031
 10. Haan YC, Diemer FS, Van Der Woude L, Van Montfrans GA, Oehlers GP, Brewster LM. The risk of hypertension and cardiovascular disease in women with uterine fibroids. *J Clin Hypertension.* (2018) 20:718–26. doi:10.1111/jch.13253.
 11. Hill AB. The environment and disease: association or causation? *Proc R Soc Med.* 1965; 58:295–300.
 12. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for life insurance. *JAMA.* 1914; 63:1752–1754.
 13. Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers MP, Franco LJ, Marcopito LF, Spooner VJ, Dyer AR, Elliott P. Blood pressure in four remote populations in the INTERSALT Study. *Hypertension.* 1989; 14:238–246. doi:10.1161/01.hyp.14.3.238.
 14. Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, Krumholz HM. Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study. *BMJ.* 2018; 362:k2357. doi:10.1136/bmj.k2357.
 15. Rahimi K, Mohseni H, Kiran A, Tran J, Nazarzadeh M, Rahimian F, Woodward M, Dwyer T, MacMahon S, Otto CM. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. *Eur Heart J.* 2018; 39:3596–3603. doi:10.1093/eurheartj/ehy486.
 16. Emdin CA, Rothwell PM, Salimi-Khorshidi G, Kiran A, Conrad N, Callender T, Mehta Z, Pendlebury ST, Anderson SG, Mohseni H, et al. Blood pressure and risk of vascular dementia: evidence from a primary care registry and a Cohort Study of transient ischemic attack and stroke. *Stroke.* 2016; 47:1429–1435. doi:10.1161/STROKEAHA.116.012658.
 17. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med.* 2015; 373:2103–2116. doi:10.1056/NEJMoa151193.
 18. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016; 387:957–967. doi:10.1016/S0140-6736(15)01225-8.
 19. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA.* 2019; 321:553–561. doi:10.1001/jama.2018.21442.
 20. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, et al; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. *Circulation.* 2006; 114:1028–1035. doi:10.1161/CIRCULATION.AHA.106.636746.
 21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015; 373:2117–2128. doi:10.1056/NEJMoa1504720.
 22. Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. *Hypertension.* 2014; 64:281–286. doi:10.1161/HYPERTENSIONAHA.114.03292.
 23. Kurioka S, Horie S, Inoue A, Mafune K, Tsuda Y, Otsuji Y. Risk of progression to hypertension in nonhypertensive Japanese workers aged 20–64 years. *J Hypertens.* 2014; 32:236–244. doi:10.1097/HJH.0000000000000031.
 24. Fuchs SC, Poli-de-Figueiredo Carlos E, Figueiredo-Neto JA, Scala LC, Whelton PK, Mosele F, de Mello RB, Vilela-Martin JF, Moreira LB, Chaves H, et al. Effectiveness of chlorthalidone plus amloride for the prevention of



hypertension: the PREVER-Prevention
randomized clinical trial. J Am Heart Assoc. 2016;
5:e004248. doi: 10.1161/JAHA.116.004248.